Investigational monotherapy for NMOSD posts promising phase 3 results
- Posted on: Sep 18 2019
- Leave a response
A novel monotherapy may reduce the risk of relapse for patients with neuromyelitis optica spectrum disorder (NMOSD), according to data presented by Genentech at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Source: AAO
Posted in: Uncategorized
